Skip to content
OpenCapital
Get started

Zoetis ZTS U.S. — Revenue

Other segment segments

International
$1.15B+16.6%

Similar metrics at other companies

Inspire Medical Systems logo
INSPUnited States — Revenue
$195.6M+1.0%
FMC Corporation logo
FMCU.S. — Revenue
$230.78M-8.0%
Axogen logo
AXGNU.S. — Revenue
$60.13M+25.7%
PROCEPT BioRobotics Corporation logo
PRCTU.S. — Revenue
$72.02M+19.4%
Titan Machinery logo
TITNU.S. — Revenue
$411.68M-9.8%
Knowles logo
KNUnited States — Revenue
$65M+17.5%

Other financials

Income statement

See full
Revenue$2.3B+2.9%
Gross profit$1.6B+2.6%
Net income$601.0M-0.2%
EPS (diluted)$1.42+6.0%

Balance sheet

See full
Cash & equivalents$1.9B+8.9%
Total debt$10.0B+48.0%
Total equity$3.2B-30.5%
Total assets$15.2B+7.5%

Cash flow

See full
Operating cash flow$401.0M-22.1%
CapEx$110.0M-38.2%
Free cash flow$291.0M-13.6%

Valuation

See full
Market cap$31.9B-54.6%
Enterprise value$39.95B-47.2%
P/E12.1×-15.1×
P/S3.4×-4.1×

Profitability

See full
Gross margin71.8%+0.8pp
Net margin27.8%+0.9pp
FCF margin23.5%0.0pp

Returns & leverage

See full
Return on equity67%+15.8pp
Debt / equity3.1×+1.6×
Current ratio3.2×+1.4×

Where this comes from

Reported directly by Zoetis in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Zoetis’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zoetis's u.s. — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zoetis's U.S. — revenue?
Zoetis (ZTS) reported U.S. — revenue of $1.09B in Q1 2026.
How has Zoetis's U.S. — revenue changed year-over-year?
Zoetis's U.S. — revenue decreased by 7.9% year-over-year, from $1.18B to $1.09B.
What is the long-term trend for Zoetis's U.S. — revenue?
Over 4 years (2021 to 2025), Zoetis's U.S. — revenue has grown at a 6.0% compound annual growth rate (CAGR), from $4.04B to $5.1B.
What does U.S. — revenue mean?
This metric represents the total gross sales generated from products and services sold within the United States market. It serves as a primary indicator of the company's market penetration and demand for its animal health portfolio in the domestic region.